SCOPE 2023: Primary Clinical Trial Concerns

Breakout session discusses the impact of incorporating decentralized elements into oncology clinical trials on data integrity, patient safety, and regulatory approvals.

With investors embracing the new regulations, a look at the progress CROs are making in their sustainability efforts

Why constant communication and transparency are paramount to successful partnerships between pharmaceutical companies and CROs

Improving the site-sponsor relationship can get trials off on the right foot and on a path for success.

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.